Generic Medicine Info
Severe renal or hepatic failure; blood disorders; hypersensitivity to sulfonamides; acute porphyria; SLE; infants ≤2 mth; pregnancy and lactation.
Special Precautions
Renal or hepatic impairment; history of allergy or asthma; AIDS; G6PD deficiency (at risk of haemolytic reactions); elderly; ensure adequate fluid intake to reduce risk of crystalluria. Discontinue if rash develops.
Adverse Reactions
Nausea, vomiting, anorexia, diarrhoea, hypersensitivity reactions, SLE, serum sickness-like syndrome, liver necrosis and hepatomegaly, myocarditis, pulmonary eosinophilia and fibrosing alveolitis, vasculitis, hypoglycaemia, hypothyroidism, neurological reactions, jaundice and kernicterus in premature neonates. Pseudomembranous colitis.
Potentially Fatal: Blood dyscrasias, Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylaxis.
C D if administered near term.
Drug Interactions
Potentiates effects of oral anticoagulants, methotrexate, phenytoin. Increased risk of crystalluria with compounds that render the urine acidic. Increased risk of blood dyscrasias with clozapine. Increased risk of hypoglycaemia with tolbutamide.
CIMS Class
ATC Classification
B05CA04 - sulfamethizole ; Belongs to the class of antiinfectives used as irrigating solutions.
D06BA04 - sulfamethizole ; Belongs to the class of topical sulfonamides used in the treatment of dermatological diseases.
S01AB01 - sulfamethizole ; Belongs to the class of antiinfectives, sulfonamides. Used in the treatment of eye infections.
J01EB02 - sulfamethizole ; Belongs to the class of short-acting sulfonamides. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on sulfamethizole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in